MAPT and Alzheimer disease: Regarding AD pathology burden, APOE carriers exhibited significantly higher whole-brain Aβ (β = 0.79; [95% CI 0.50, 1.09]; t = 5.335; p < 0.001; Fig. 2B) and entorhinal tau burden (β = 0.32; [95% CI 0.01, 0.63]; t = 2.040; p = 0.043; Fig. 2C).